Clinical Development Contract Manufacturing Hormones 
Pharmaceutical Technology
NOVEMBER 30, 2022
We’re using a combination of gut hormones to mimic the effectiveness of bariatric surgery. Mounjaro is a combination of the two gut hormones GLP-1 and GIP. Manufacturing for Wegovy was also hit when a contract manufacturer in charge of syringe filling halted deliveries due to issues with good manufacturing practices.
Pharmaceutical Technology
FEBRUARY 24, 2023
(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Genital Warts (Condylomata Acuminata). The company also offers contract manufacturing and laboratory services.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
FEBRUARY 24, 2023
(Lopinavir + ritonavir) is under clinical development by Douglas Pharmaceuticals and currently in Phase I for Cervical Intraepithelial Neoplasia (CIN). The company also offers contract manufacturing and laboratory services.
Pharmaceutical Technology
NOVEMBER 30, 2022
We’re using a combination of gut hormones to mimic the effectiveness of bariatric surgery. Mounjaro is a combination of the two gut hormones GLP-1 and GIP. Manufacturing for Wegovy was also hit when a contract manufacturer in charge of syringe filling halted deliveries due to issues with good manufacturing practices.
Pharmaceutical Technology
FEBRUARY 27, 2023
Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Multiple Myeloma. EU, Asia and Japan and for non-metastatic high risk hormone sensitive prostate cancer. The drug candidate is also under development for castration-resistant prostate cancer in the Japan as a tablet formulation.
Pharmaceutical Technology
FEBRUARY 27, 2023
Enzalutamide is under clinical development by Pfizer and currently in Phase I for Myelofibrosis. EU, Asia and Japan and for non-metastatic high risk hormone sensitive prostate cancer. The drug candidate is also under development for castration-resistant prostate cancer in the Japan as a tablet formulation.
Pharmaceutical Technology
FEBRUARY 27, 2023
Enzalutamide is under clinical development by Pfizer and currently in Phase I for Relapsed Chronic Lymphocytic Leukemia (CLL). EU, Asia and Japan and for non-metastatic high risk hormone sensitive prostate cancer. Pfizer sells its products through wholesalers, retailers, hospitals, clinics, government agencies and pharmacies.
Expert insights. Personalized for you.
264 
Let's personalize your content